ArticleJournal of cellular and molecular medicine2024
Prognostic heterogeneity of Ki67 in non-small cell lung cancer: A comprehensive reappraisal on immunohistochemistry and transcriptional data.
Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Conventional chest CT features are associated with Ki-67 labeling index in lung adenocarcinoma: a single-center retrospective radiopathologic study.Journal of thoracic disease · 2026Article
- Predictive modeling of immunotherapy efficacy in driver gene-negative non-small cell lung cancer.Translational lung cancer research · 2026Article
- Prediction of lymph node metastasis in non-small cell lung cancer and its correlation with Ki-67 expression: a comparative study between intravoxel incoherent motion imaging andBMC medical imaging · 2026Article
- From algorithm to verification: based on network toxicology and machine learning, the immunomodulatory role of IGFBP1/MKI67/C9 in perfluorooctanoic acid-induced osteoarthritis was discovered, and a diagnostic model was constructed.Frontiers in immunology · 2026Article
- Prediction of the Ki-67 proliferation index in lung adenocarcinoma using an interpretable CT-based deep learning radiomics model: a two-center study.BMC pulmonary medicine · 2025Article
- Development and internal validation of a preoperative prediction model for postoperative pneumonia in lung cancer patients: a retrospective study.BMC surgery · 2025Article
- Ki-67 expression stratifies PD-L1-high NSCLC for immune checkpoint inhibitor plus chemotherapy: a real-world biomarker validation.Cancer immunology, immunotherapy : CII · 2025Article
- Cancer-Associated Fibroblasts as the "Architect" of the Lung Cancer Immune Microenvironment: Multidimensional Roles and Synergistic Regulation with Radiotherapy.International journal of molecular sciences · 2025Review
- Prediction of Ki-67 Expression in HIV-Associated Lung Adenocarcinoma Patients Using Multiple Machine Learning Models Based on CT Imaging Radiomics.Cancer management and research · 2025Article
- Prognostic heterogeneity of Ki67 in non-small cell lung cancer: A comprehensive reappraisal on immunohistochemistry and transcriptional data.Journal of cellular and molecular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In the present study, the debatable prognostic value of Ki67 in patients with non-small cell lung cancer (NSCLC) was attributed to the heterogeneity between lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC). Based on meta-analyses of 29 studies, a retrospective immunohistochemical cohort of 1479 patients from our center, eight transcriptional datasets and a single-cell datasets with 40 patients, we found that high Ki67 expression suggests a poor outcome in LUAD, but conversely, low Ki67 expression indicates worse prognosis in LUSC. Furthermore, low proliferation in LUSC is associated with higher metastatic capacity, which is related to the stronger epithelial-mesenchymal transition potential, immunosuppressive microenvironment and angiogenesis. Finally, nomogram model incorporating clinical risk factors and Ki67 expression outperformed the basic clinical model for the accurate prognostic prediction of LUSC. With the largest prognostic assessment of Ki67 from protein to mRNA level, our study highlights that Ki67 also has an important prognostic value in NSCLC, but separate evaluation of LUAD and LUSC is necessary to provide more valuable information for clinical decision-making in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.